383 related articles for article (PubMed ID: 16098233)
1. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69.
Amicosante M; Berretta F; Rossman M; Butler RH; Rogliani P; van den Berg-Loonen E; Saltini C
Respir Res; 2005 Aug; 6(1):94. PubMed ID: 16098233
[TBL] [Abstract][Full Text] [Related]
2. Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test.
Amicosante M; Deubner D; Saltini C
Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct; 22(3):175-9. PubMed ID: 16315779
[TBL] [Abstract][Full Text] [Related]
3. Major histocompatibility locus genetic markers of beryllium sensitization and disease.
Saltini C; Richeldi L; Losi M; Amicosante M; Voorter C; van den Berg-Loonen E; Dweik RA; Wiedemann HP; Deubner DC; Tinelli C
Eur Respir J; 2001 Oct; 18(4):677-84. PubMed ID: 11716174
[TBL] [Abstract][Full Text] [Related]
4. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells.
Amicosante M; Berretta F; Franchi A; Rogliani P; Dotti C; Losi M; Dweik R; Saltini C
Eur Respir J; 2002 Nov; 20(5):1174-8. PubMed ID: 12449171
[TBL] [Abstract][Full Text] [Related]
5. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease.
Maier LA; McGrath DS; Sato H; Lympany P; Welsh K; Du Bois R; Silveira L; Fontenot AP; Sawyer RT; Wilcox E; Newman LS
J Immunol; 2003 Dec; 171(12):6910-8. PubMed ID: 14662898
[TBL] [Abstract][Full Text] [Related]
6. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity.
Rosenman KD; Rossman M; Hertzberg V; Reilly MJ; Rice C; Kanterakis E; Monos D
Occup Environ Med; 2011 Jul; 68(7):487-93. PubMed ID: 21186201
[TBL] [Abstract][Full Text] [Related]
7. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.
Fontenot AP; Torres M; Marshall WH; Newman LS; Kotzin BL
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12717-22. PubMed ID: 11050177
[TBL] [Abstract][Full Text] [Related]
8. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain.
Bill JR; Mack DG; Falta MT; Maier LA; Sullivan AK; Joslin FG; Martin AK; Freed BM; Kotzin BL; Fontenot AP
J Immunol; 2005 Nov; 175(10):7029-37. PubMed ID: 16272364
[TBL] [Abstract][Full Text] [Related]
9. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity.
Rossman MD; Stubbs J; Lee CW; Argyris E; Magira E; Monos D
Am J Respir Crit Care Med; 2002 Mar; 165(6):788-94. PubMed ID: 11897645
[TBL] [Abstract][Full Text] [Related]
10. Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease.
Weston A; Ensey J; Kreiss K; Keshava C; McCanlies E
Am J Ind Med; 2002 Jun; 41(6):457-65. PubMed ID: 12173370
[TBL] [Abstract][Full Text] [Related]
11. Role of high-affinity HLA-DP specific CLIP-derived peptides in beryllium binding to the HLA-DPGlu69 berylliosis-associated molecules and presentation to beryllium-sensitized T cells.
Amicosante M; Berretta F; Dweik R; Saltini C
Immunology; 2009 Sep; 128(1 Suppl):e462-70. PubMed ID: 19191908
[TBL] [Abstract][Full Text] [Related]
12. Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity.
Rogliani P; Amicosante M; Berretta F; Dotti C; Bocchino M; O'Donnell KM; Saltini C
Int J Immunopathol Pharmacol; 2004; 17(2 Suppl):3-10. PubMed ID: 15345185
[TBL] [Abstract][Full Text] [Related]
13. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69.
Amicosante M; Sanarico N; Berretta F; Arroyo J; Lombardi G; Lechler R; Colizzi V; Saltini C
Hum Immunol; 2001 Jul; 62(7):686-93. PubMed ID: 11423174
[TBL] [Abstract][Full Text] [Related]
14. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles.
Wang Z; White PS; Petrovic M; Tatum OL; Newman LS; Maier LA; Marrone BL
J Immunol; 1999 Aug; 163(3):1647-53. PubMed ID: 10415070
[TBL] [Abstract][Full Text] [Related]
15. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization.
McCanlies EC; Ensey JS; Schuler CR; Kreiss K; Weston A
Am J Ind Med; 2004 Aug; 46(2):95-103. PubMed ID: 15273960
[TBL] [Abstract][Full Text] [Related]
16. Function associated transforming growth factor-beta gene polymorphism in chronic beryllium disease.
Gaede KI; Amicosante M; Schürmann M; Fireman E; Saltini C; Müller-Quernheim J
J Mol Med (Berl); 2005 May; 83(5):397-405. PubMed ID: 15750822
[TBL] [Abstract][Full Text] [Related]
17. Analysis of TNF-alpha promoter polymorphisms in the susceptibility to beryllium hypersensitivity.
Dotti C; D'Apice MR; Rogliani P; Novelli G; Saltini C; Amicosante M
Sarcoidosis Vasc Diffuse Lung Dis; 2004 Mar; 21(1):29-34. PubMed ID: 15127972
[TBL] [Abstract][Full Text] [Related]
18. Interaction of genetic and exposure factors in the prevalence of berylliosis.
Richeldi L; Kreiss K; Mroz MM; Zhen B; Tartoni P; Saltini C
Am J Ind Med; 1997 Oct; 32(4):337-40. PubMed ID: 9258386
[TBL] [Abstract][Full Text] [Related]
19. Ethical considerations in testing workers for the -Glu69 marker of genetic susceptibility to chronic beryllium disease.
Silver K; Sharp RR
J Occup Environ Med; 2006 Apr; 48(4):434-43. PubMed ID: 16607200
[TBL] [Abstract][Full Text] [Related]
20. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease.
Fontenot AP; Maier LA
Trends Immunol; 2005 Oct; 26(10):543-9. PubMed ID: 16099719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
